Sanofi and Regeneron’s dupilumab has been given a priority review by the FDA, putting the first-in-class drug on course for a likely approval by 29 March. The drug is for adult patients with ...
18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...
The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback